Angel David Montijo Valdés

Mr. Angel David Montijo Valdés

Biomoléculas, Instituto Nacional de Pediatria, Mexico City, Ciudad de México, Mexico
orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2025 in Microorganisms
Verified
Journal Article
Open access
PDF file
Enrique SanhuezaEnrique Sanhueza
Enrique Sanhueza
CRCassiopeia Cantero Ramírez
Cassiopeia Cantero Ramírez
AVAngel David Montijo Valdés
Angel David Montijo Valdés
CVCinthya Guadalupe Rodríguez Valladeres
Cinthya Guadalupe Rodríguez Valladeres
Cynthia Fernandez-LainezCynthia Fernandez-Lainez
Cynthia Fernandez-Lainez
Gabriel López-VelázquezGabriel López-Velázquez
Gabriel López-Velázquez
Cardiovascular diseases (CVDs) have become one of the major global health crises of the last century, causing millions of deaths each year, and are the leading cause of disability worldwide. The pharmacological management of these conditions demands new alternative or complementary therapies due to the multiple long-term side effects experienced by patients. In this context, exopolysaccharides (EPSs) have emerged as a promising alternative due to their numerous functional properties and favorable biotechnological and medical applications for health. This review provides an overview of the properties of EPSs as bioactive agents in cardiovascular diseases, highlighting the cellular signaling mechanisms in their role as cardioprotective agents, with a primary focus on their roles as antioxidants, antihypertensives, and cholesterol regulators, and their regenerative effects on vascular epithelia, positioning EPSs as promising biomolecules for CVD prevention.